1 / 34

1 st half-year results 2009 Information meeting of 15 September 2009

1 st half-year results 2009 Information meeting of 15 September 2009 . Contents. Business in the 1 st half of 2009 Prospects for the 2 nd half of 2009 Conclusion. Business in the 1 st half of 2009. Changing pharmacy market

Melvin
Download Presentation

1 st half-year results 2009 Information meeting of 15 September 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1st half-year results 2009Information meeting of 15 September 2009

  2. Contents Business in the 1st half of 2009 Prospects for the 2nd half of 2009 Conclusion

  3. Business in the 1st half of 2009

  4. Changing pharmacy market Continued actions by public authorities to control health expenditure Rise of generics Self-medication products on open access May 2009: the European Court of Justice gave its verdict against opening up dispensing pharmacies’ capital HPST (hospitals, patients, health, territories) law: positive effects for pharmacists Even if, from a purely economic point of view, the 1st half-year did not lead to any real upturn for pharmacists, a certain number of decisions strengthened the profession and the pharmacist’s role in protecting public health. In this context, pharmacists need effective support more than ever HIGHLIGHTS Economic context 1st half of 2009

  5. HIGHLIGHTS Pharmacy Business France • More than 5,000 pharmacies equipped with LGPI/CIP-GS on 30/06 out of a total of 9,800 customers • 2.5 % rise in Turnover over the 1st half of 2009 • Configuration sales stable (- 0.4 %) • Licences slightly down (-1.37 %) • Recurrent T/O up 6.95 % • Demonstrates once more the relevance of the Pharmagest Group’s business model.

  6. Pharmacy Business France HIGHLIGHTS T/O boosted thanks to the satellite offer of high-margin products up 18.28 % compared with the 1st half of 2008. • For example: • To date, 1,300 pharmacies use one of the Group’s advertising tools at the point of sale (compared with 500 at the end of 2008), following Pharmagest’s acquisition of the Novax software and databases after that company’s compulsory liquidation: • 970 Offimédia contracts (contextual advertising tool developed by Pharmagest) • 330 Pharmaxess customers (tool developed by Novax for which Pharmagest now provides maintenance) • The PD (Pharmaceutical Dossier) is now in general use and has had a positive impact on our secure Internet access product Offisecure, up 33 % during the 1st half of 2009. • CNOP has just reported the 10,000th pharmacy to be connected to the PD • 62 % of the Pharmagest Group’s customers equipped with LGPI/CIP-GS have activated the PD

  7. HIGHLIGHTS Pharmacy Business BENELUX • SABCO/PHARMAGEST: • 12.5 % share of the market in Belgium and 43 % in • Luxembourg • 678 customers, 2,300 stations installed • of which 143 customers equipped with the new Sabco Optimum and Ultimate solutions • T/O: 1.3 M€ (- 13 % compared with the 1st half of 2008) • in a context • of reorganising the managerial and sales structure • of putting the Pharmagest business model in place (30 months’ free maintenance)

  8. HIGHLIGHTS Laboratories Business The Laboratories business grew 11.4 % in the 1st half of 2009 • After a very difficult year for Laboratories in 2008 with direct repercussions on our product offer, the 1st half of 2009 shows that they have a new trust in the market. • 1st half-year growth of our: • information campaigns on the therapeutic environment, • contextual advertising • and online surveys • Our innovative Offidirect services (orders placed directly by the Pharmacist with the Laboratory without going through a distributor) as well as the Advertising Agency also continue to grow steadily.

  9. HIGHLIGHTS Laboratories Business FIRST BAROMETER OF HEALTH INFORMATION • Pharmagest, in conjunction with Intermedix and IDS Santé, carried out a large national survey amongst 3 target groups: Pharmacists, Doctors, and Internet users • This barometer is an opportunity each year to measure changes in the needs of these 3 target groups and to understand the new problems they face. • The presentation of the results of this study to the different operators in the pharmaceutical industry on 3 July 2009 aroused great interest and made it possible to establish new, promising contacts.

  10. Pharmagest strengthens its presence in the high-growth EHPAD sector After the strategic acquisition of MALTA Informatique, in April 2009 Pharmagest announced the acquisition of AZUR Software, a company which designs and publishes a range of management software for care homes for the elderly. Acquisition method: purchase of Azur Software’s business financed with a bank loan. The number of EHPAD customers thus increased to 750 (Malta + Azur) and the share of the sector market to 7 % (out of a total of 11,000 existing care homes). The software range offered by Malta Informatique, and more especially the reference software for EHPADs, TITAN, is now strengthened by Azur Software’s software MdRWIN, MEDIC and EHPADIAG, the latter being the main software on the market for self-evaluation of the quality of these institutions. MALTA INFORMATIQUE NEW EXTERNAL GROWTH IN I.T. FOR EHPADs (CARE HOMES FOR THE ELDERLY)

  11. T/O for the 1st half of 2009 was 465 K€ (+ 56 %) The number of new customers (44 during the 1st half-year) and of migrations of old Azur solutions to TITAN, clearly shows Malta’s commercial dynamism Continued strengthening of quality product offer The combining of the two teams as well as newly hired staff strengthen Malta’s geographic presence for customer service. Malta Informatique • Extremely dynamic business with T/O growth of over 50 %

  12. In April 2009, Pharmagest set up VIP Pharma which acquired the “Gold Partner’s Card” business line from VISEOPHARMA. Business: promoting loyalty programmes for dispensing pharmacists Principle: VIP Pharma acts as an intermediary and provides the logistics between the pharmacist and its Laboratory partners. The pharmacist proposes a sales promotion card to his customers Sales of partner products earn points In return for the points, the customer can receive free partner products. VIP PHARMA NEW OFFER FOR PHARMACISTS Pharmagest invests in building loyalty of pharmacists’ customers

  13. Financial results on 30 June 2009

  14. Financial results on 30 June 2009 Key figures

  15. Financial results on 30 June 2009 Consolidated by business • The “configuration sales” business (hardware, network, licences) accounts for 60 % of the total turnover for HY1 2009 compared with 62 % in HY1 2008 • The “maintenance, data bases” business accounts for 30.1 % of the total turnover for HY1 2009 compared with 29.4 % in HY1 2008 • The “laboratories” business accounts for 3.54 % of the total turnover for HY1 2009 compared with 3.26 % in HY1 2008 • New products account for 6.47 % of the total turnover for HY1 2009 compared with 5.6 % in HY1 2008, growth of 15.5 %

  16. Profit and loss account Financial results on 30 June 2009

  17. Balance sheet Financial results on 30 June 2009 * Item exceptionally high as a result of a large number of requests for financing from our customers being frozen by GE Capital, regularized in January 2009

  18. (*) Excluding securities available for sale 15.6 M€ (**) Of which R&D – 0.8 M€ Financial results on 30 June 2009 Cash flow summary

  19. MARKET CAPITALISATION On 30/06/2009, market capitalisation reached 114.4 M€. On 03/09/2009, it was 120.75 M€

  20. Share price trend since September 2008(on 4 September 2009)

  21. PROSPECTS

  22. EHPAD Business

  23. Full order books which lead us to expect explosive growth of the business The TITAN software is seen more and more as an essential “core EHPAD business” solution offering a wide range of modules which reinforces its key position. Continuous innovation policy put in place Development of “global healthcare pricing”, integrating medicines into EHPADs’ budgets as well as the monitoring of medical and para-medical acts. Prospects EHPAD Business

  24. PHARMACY FRANCE

  25. Prospects Pharmacy France A significant growth lever for turnover and gross margin

  26. Continued growth of turnover and profitability despite the difficult economic context Thanks to improved productivity And to continuing to build customer loyalty and expanding our service offer (training, local monitoring). Increasing the rate of migrations from traditional solutions to LGPI/CIP-GS. Mass promotion of our high-margin products and service offers European development: Serious study of external growth in progress Prospects Pharmacy France

  27. PHARMACY BENELUX

  28. Commercial business Search for agreements with pharmacy chains based on LGPI and Officentral LGPI as well as our satellite offers available since June in multilingual versions making it possible to speed up deployment in Flanders (currently 6% share of the market) Launch of our Offimedia product in Flanders and Luxembourg Reorganisation Resources put in place to strengthen our presence in Flanders Thanks to the ongoing reorganisation, we are aiming at our turnover for 2009 recovering to a figure equivalent to that in 2008. Prospects Pharmacy BENELUX

  29. LABORATORIES

  30. Prospects Laboratories • Commercial business • Favourable context since the start of 2009 with active canvassing and new partnerships • Acquisition of new customers and building loyalty of large accounts • Development of the Advertising Agency business • Development of the reputation of the Carevox.fr website (100,000 visitors/month) by advertising operations with a view to the site being included in advertising products dedicated to the pharmaceutical industry

  31. Conclusion

  32. A business model offering a dynamic of steady business growth An excellent margin level Promising new business sectors An international development strategy which is becoming clearer Conclusion

  33. Conclusion Next Meetings • Investors’ meeting: • MID CAP EVENT PARIS 21 and 22September 2009 • Financial publication: • Letter to shareholders October2009 • Q3 2009 T/O press release 12 November 2009

  34. Contacts Managing Director Thierry CHAPUSOT Thierry.chapusot@pharmagest.com Shareholder and Investor Relations  Anne LHOTE Tel.: 03 83 15 90 67 –anne.lhote@welcoop.com Press Relations FIN’EXTENSO Isabelle APRILE Tel.: 33 1 39 97 61 22 - i.aprile@finextenso.fr

More Related